MK-3102
Total Payments
$862,067
Transactions
363
Doctors
4
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $8,447 | 1 | 0 |
| 2018 | $15,716 | 3 | 1 |
| 2017 | $837,904 | 359 | 3 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $861,473 | 360 | 99.9% |
| Consulting Fee | $593.75 | 3 | 0.1% |
Payments by Type
Research
$861,473
360 transactions
General
$593.75
3 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess Cardiovascular Outcomes Following Treatment with MK-3102 in Subjects With Type 2 Diabetes Mellitus | Merck Sharp & Dohme Corporation | $812,648 | 2 |
| A Multicenter, Randomized, Double-Blind Study to Evaluate the Safety, Tolerablility, and Efficacy of the Addition of MK-3102 to Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Therapy | Merck Sharp & Dohme Corporation | $45,822 | 0 |
| A Multicenter, Phase III, Randomized, Placebo-Controlled Trial to Assess the Safety and Efficacy of MK-3102 Monotherapy in Subjects with Type 2 Diabetes Mellitus and Inadequate Glycemic Control | Merck Sharp & Dohme Corporation | $2,000 | 0 |
| A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of MK-3102 in 18 and 45 Year-Old Subjects with Type 2 Diabetes Mellitus and Inadequate Glycemic Control | Merck Sharp & Dohme Corporation | $1,002 | 0 |
Top Doctors Receiving Payments for MK-3102
Ad
Manufacturing Companies
- Merck Sharp & Dohme Corporation $862,067
Product Information
- Type Drug
- Total Payments $862,067
- Total Doctors 4
- Transactions 363
About MK-3102
MK-3102 is a drug associated with $862,067 in payments to 4 healthcare providers, recorded across 363 transactions in the CMS Open Payments database. The primary manufacturer is Merck Sharp & Dohme Corporation.
Payment data is available from 2017 to 2020. In 2020, $8,447 was paid across 1 transactions to 0 doctors.
The most common payment nature for MK-3102 is "Unspecified" ($861,473, 99.9% of total).
MK-3102 is associated with 4 research studies, including "A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess Cardiovascular Outcomes Following Treatment with MK-3102 in Subjects With Type 2 Diabetes Mellitus" ($812,648).